Literature DB >> 8590435

Tissue fibronectin levels of human prostatic cancer, as a tumor marker.

H Sönmez1, S Süer, I Karaarslan, H Baloğlu, E Kökoğlu.   

Abstract

In this study, tissue fibronectin levels have been assayed in human prostatic cancer, benign prostatic hyperplasia and normal prostatic tissue. The mean tissue fibronectin levels for prostatic cancer, benign prostatic hyperplasia and normal groups were found to be 20.22 +/- 8.66 micrograms/mg protein and 11.77 +/- 6.74 micrograms/mg protein, respectively. In the malignant group, the mean fibronectin concentrations, appeared to be significantly higher than normal, (p < 0.05). On the other hand, fibronectin levels of benign prostatic hyperplasia were found to be statistically insignificant in comparison to the normal group (p > 0.05).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590435

Source DB:  PubMed          Journal:  Cancer Biochem Biophys        ISSN: 0305-7232


  15 in total

1.  MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.

Authors:  Mingqian Tan; Susan M Burden-Gulley; Wen Li; Xueming Wu; Daniel Lindner; Susann M Brady-Kalnay; Vikas Gulani; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2011-12-03       Impact factor: 4.200

2.  Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.

Authors:  Xueming Wu; Guanping Yu; Daniel Lindner; Susann M Brady-Kalnay; Qi Zhang; Zheng-Rong Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-07-15

Review 3.  The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.

Authors:  V Baron; E D Adamson; A Calogero; G Ragona; D Mercola
Journal:  Cancer Gene Ther       Date:  2006-02       Impact factor: 5.987

4.  Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.

Authors:  J M Boer; W K Huber; H Sültmann; F Wilmer; A von Heydebreck; S Haas; B Korn; B Gunawan; A Vente; L Füzesi; M Vingron; A Poustka
Journal:  Genome Res       Date:  2001-11       Impact factor: 9.043

5.  Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.

Authors:  A P Stubbs; P D Abel; M Golding; G Bhangal; Q Wang; J Waxman; G W Stamp; E N Lalani
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

Review 6.  Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?

Authors:  Gabriela Rennebeck; Matthew Martelli; Natasha Kyprianou
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

7.  Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.

Authors:  Zheng Han; Yajuan Li; Sarah Roelle; Zhuxian Zhou; Yuchi Liu; Rob Sabatelle; Aidan DeSanto; Xin Yu; Hui Zhu; Cristina Magi-Galluzzi; Zheng-Rong Lu
Journal:  Bioconjug Chem       Date:  2017-03-09       Impact factor: 4.774

8.  Synthesis and evaluation of a targeted nanoglobular dual-modal imaging agent for MR imaging and image-guided surgery of prostate cancer.

Authors:  Mingqian Tan; Zhen Ye; Daniel Lindner; Susann M Brady-Kalnay; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2013-03-08       Impact factor: 4.200

9.  Silibinin inhibits fibronectin induced motility, invasiveness and survival in human prostate carcinoma PC3 cells via targeting integrin signaling.

Authors:  Gagan Deep; Rahul Kumar; Anil K Jain; Chapla Agarwal; Rajesh Agarwal
Journal:  Mutat Res       Date:  2014-10       Impact factor: 2.433

10.  Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.

Authors:  Yajuan Li; Zheng Han; Sarah Roelle; Aidan DeSanto; Rob Sabatelle; Rebecca Schur; Zheng-Rong Lu
Journal:  Mol Pharm       Date:  2017-10-25       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.